Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

Rubin, Joseph; A. Ajani, Jaffer; J. Schirmer, William; P. Venook, Alan; M. Bukowski, Ronald; F. Pommier, Rodney; B. Saltz, Leonard; Dandona, Paresh; Anthony, Lowell

doi:10.1200/jco.1999.17.2.600

Public

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

Published in Journal of Clinical Oncology • Feb 1, 1999

Authors:

Joseph Rubin

Jaffer A. Ajani

William J. Schirmer

Abstract

PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular ...

Subject

Octreotide

Medicine

Carcinoid syndrome

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!